Regulus Therapeutics Inc. - FORM 10-Q - EX-10.2 - EXHIBIT 10.2 - August 1, 2017

Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - Regulus Therapeutics Inc.ex-321x20170630.htm
EX-31.2 - EXHIBIT 31.2 - Regulus Therapeutics Inc.ex-312x20170630.htm
EX-31.1 - EXHIBIT 31.1 - Regulus Therapeutics Inc.ex-311x20170630.htm
EX-10.3 - EXHIBIT 10.3 - Regulus Therapeutics Inc.ex-103xgrintpaulseparation.htm
EX-10.1 - EXHIBIT 10.1 - Regulus Therapeutics Inc.ex-101xdeegmarkemploymenta.htm
10-Q - 10-Q - Regulus Therapeutics Inc.rgls20170630-10q.htm

Exhibit 10.2

Joseph P. Hagan Compensation Changes

As part of his appointment to President and Chief Executive Officer, the Board of Directors increased Mr. Hagan’s base annual compensation to $500,000 and his target bonus to 50% of his base salary, effective May 4, 2017.


Regulus Therapeutics Inc. Reports